




For Professional Use Only

AmpliSens[®] MTC-diff-FRT
PCR kit
Instruction Manual

AmpliSens[®]



Ecoli s.r.o., Studenohorska 12
841 03 Bratislava 47
Slovak Republic
Tel.: +421 2 6478 9336
Fax: +421 2 6478 9040



Federal Budget Institute of
Science "Central Research
Institute for Epidemiology"
3A Novogireevskaya Street
Moscow 111123 Russia

TABLE OF CONTENTS

1. INTENDED USE	3
2. PRINCIPLE OF PCR DETECTION	3
3. CONTENTS.....	4
4. ADDITIONAL REQUIREMENTS	4
5. GENERAL PRECAUTIONS.....	5
6. SAMPLING AND HANDLING	6
7. WORKING CONDITIONS.....	6
8. PROTOCOL	6
9. DATA ANALYSIS	8
10. TROUBLESHOOTING.....	12
11. TRANSPORTATION.....	12
12. STABILITY AND STORAGE.....	12
13. SPECIFICATIONS.....	13
14. REFERENCES	14
15. QUALITY CONTROL.....	15
16. KEY TO SYMBOLS USED	15

1. INTENDED USE

AmpliSens® MTC-diff-FRT PCR kit is an *in vitro* nucleic acid amplification test for differentiation of the DNA of *Mycobacterium tuberculosis complex (MTC)* including the human (*M.tuberculosis*), the bovine (*M.bovis*) and also the vaccine (*M.bovis* BCG) strains in the clinical material and microorganism cultures using real-time fluorescence hybridization detection of amplified products.



The results of PCR analysis are taken into account in complex diagnostics of disease.



This analysis requires the use of DNA samples extracted from clinical material or microorganism cultures, in which *MTC* DNA was previously detected or quantitatively identified.

2. PRINCIPLE OF PCR DETECTION

Differentiation between the *Mycobacteria* DNA, extracted from the clinical material or microorganism cultures, uses multiprimer PCR with simultaneous amplification of the four DNA fragments, three of them act as specific targets, determining one of the strains from the *Mycobacterium tuberculosis complex*: *M.tuberculosis*, *M.bovis* or *M.bovis* BCG, the fourth DNA fragment is the Internal Control. The reaction mix contains fluorescently labeled oligonucleotide probes, which hybridize to the complementary regions of the DNA targets being amplified, leading to the increase of fluorescent intensity. Fluorescent-hybridization detection of amplification products signals is carried out directly during the PCR analysis with the aid of the thermocycler in the “real-time” mode.

AmpliSens® MTC-diff-FRT PCR kit is a qualitative test that uses the Internal Control STI-87 (IC) from **AmpliSens® MTC-FRT** PCR kit. It must be used in the extraction procedure in order to control the extraction process of each individual sample and to identify possible reaction inhibition.

AmpliSens® MTC-diff-FRT PCR kit uses “hot-start”, which greatly reduces the frequency of nonspecifically primed reactions. “Hot-start” is guaranteed by the separation of nucleotides and Taq-polymerase using chemically modified polymerase (TaqF). The chemically modified polymerase (TaqF) is activated by heating at 95 °C for 15 min.

AmpliSens® MTC-diff-FRT PCR kit contains **Enzyme UDG** to reduce the risk of contamination by amplification products in PCR laboratory.

3. CONTENTS

AmpliSens[®] *MTC-diff-FRT* PCR kit is produced in 1 form:

AmpliSens[®] *MTC-diff-FRT* PCR kit variant FRT, **REF** R-B80(RG,iQ,Dt,SC)-CE

AmpliSens[®] *MTC-diff-FRT* PCR kit variant FRT includes:

<i>Reagent</i>	<i>Description</i>	<i>Volume, ml</i>	<i>Quantity</i>
PCR-mix-1-FL <i>MTC-diff</i>	colorless clear liquid	0.28	2 tubes
PCR-mix-2-FRT	colorless clear liquid	0.3	1 tube
Polymerase (TaqF)	colorless clear liquid	0.03	1 tube
Enzyme UDG	colorless clear liquid	0.03	1 tube
Positive Control DNA <i>MTC-diff / STI</i> (C+ <i>MTC-diff / STI</i>)	colorless clear liquid	0.1	1 tube
TE-buffer	colorless clear liquid	0.5	1 tube

AmpliSens[®] *MTC-diff-FRT* PCR kit is intended for 55 reactions (including controls).

4. ADDITIONAL REQUIREMENTS

- Disposable powder-free gloves and a laboratory coat.
- Pipettes (adjustable).
- Sterile RNase-free pipette tips with aerosol filters (up to 200 µl).
- Tube racks.
- Vortex mixer.
- Desktop centrifuge with a rotor for 2-ml reaction tubes.
- PCR box.
- Real-time instruments (for example, Rotor-Gene 3000/6000 (Corbett Research, Australia); Rotor-Gene Q (QIAGEN, Germany), iCycler iQ5 (Bio-Rad, USA); Mx3000P, Mx3005 (Stratagene, USA), SmartCycler II (provided with Mini-Spin centrifuge) (Cepheid, USA).
- Disposable polypropylene PCR tubes (0.1- or 0.2-ml) when working with PCR kit variant FRT-100 F:
 - a) 0.2-ml PCR tubes with optical transparent domed or flat caps if a plate-type instrument is used;
 - b) 0.2-ml PCR tubes with flat caps or strips of four 0.1-ml Rotor-Gene PCR tubes if a rotor-type instrument is used.
 - c) Specific reaction tubes for SmartCycler II instrument.

- Refrigerator with temperature range from minus 2 to minus 8 °C.
- Deep-freezer at the temperature from minus 24 to minus 16 °C.
- Reservoir for used tips.

5. GENERAL PRECAUTIONS

The user should always pay attention to the following:

- Use sterile pipette tips with aerosol barriers and use new tip for every procedure.
- Store all extracted positive material (samples, controls and amplicons) away from all other reagents and add it to the reaction mix in a distantly separated facility.
- Thaw all components thoroughly at room temperature before starting an assay.
- When thawed, mix the components and centrifuge briefly.
- Use disposable protective gloves and laboratory cloths, and protect eyes while samples and reagents handling. Thoroughly wash hands afterward.
- Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in laboratory work areas.
- Do not use a kit after its expiration date.
- Dispose of all samples and unused reagents in compliance with local requirements.
- Samples should be considered potentially infectious and handled in a biological cabinet in accordance with appropriate biosafety practices.
- Clean and disinfect all sample or reagent spills using a disinfectant, such as 0.5 % sodium hypochlorite or another suitable disinfectant.
- Avoid samples and reagents contact with the skin, eyes and mucous membranes. If these solutions come into contact, rinse the injured area immediately with water and seek medical advice immediately.
- Material Safety Data Sheets (MSDS) are available on request.
- Use of this product should be limited to personnel trained in DNA amplification techniques.
- Workflow in the laboratory must be one-directional, beginning in the Extraction Area and moving to the Amplification and Detection Area. Do not return samples, equipment, and reagents to the area where the previous step was performed.



Some components of this kit contain sodium azide as a preservative. Do not use metal tubing for reagent transfer.

6. SAMPLING AND HANDLING



Obtaining samples of biological materials for PCR-analysis, transportation, and storage are described in the manufacturer's handbook [1]. It is recommended that this handbook is read before starting work.

AmpliSens[®] MTC-diff-FRT PCR kit is intended as a supplement test for **AmpliSens[®] MTC-FRT** PCR kit and is used for analysis of the DNA previously extracted from the clinical material. Please, consult the **AmpliSens[®] MTC-FRT** PCR kit *Instructions Manual* for further information on sampling and pre-treatment procedures.

7. WORKING CONDITIONS

AmpliSens[®] MTC-diff-FRT PCR kit should be used at 18–25 °C.

8. PROTOCOL

8.1. DNA extraction

AmpliSens[®] MTC-diff-FRT PCR kit is intended as a supplement test for **AmpliSens[®] MTC-FRT** PCR kit and is used for analysis of the DNA previously extracted from the clinical material. The **Internal Control STI-87 (IC)** used for this experiment is also taken from **AmpliSens[®] MTC-FRT** PCR kit, thus consult the **AmpliSens[®] MTC-FRT** PCR kit *Instructions Manual* for further information.



Extract the DNA according to the manufacturer's protocol.

8.2. Preparing PCR

8.2.1 Preparing tubes for PCR



Tube selection depends on the thermocycler with “real-time” detection system being used.



Components of the reaction mix should be mixed directly before use.

1. Prepare the required number of tubes for amplification including the number of test samples and control samples (2 amplification controls).
2. Prepare the reaction mix in 1.5 ml tube for each reaction:
 - **10 µl of PCR-mix-1-FL MTC-diff**
 - **5 µl of PCR-mix-2-FRT**
 - **0.5 µl of Polymerase (TaqF)**
 - **0.5 µl of Enzyme UDG**

Vortex the tubes until the drops are settled from the lids.

3. Add **15 µl** of the prepared reaction mix to each tube.
4. Prepare the tubes with extracted DNA, in which *Mycobacterium tuberculosis complex* (MTC) DNA was previously found with the aid of **AmpliSens® MTC-FRT** PCR kit. In case of the need to store the tubes, vortex the tubes and then centrifuge at 10,000 rpm for 2 min.
5. To the prepared tubes add **10 µl** of **DNA samples**.



Avoid transferring the sorbent to the reaction mixture, if using DNA-sorb extraction techniques.



DNA samples obtained previously can be used for analysis, given that it was stored during 1 week at a temperature from minus 2 to minus 8°C, during 1 year at a temperature ≤16°C, any period of storage at a temperature ≤68°C.

6. Carry out the control amplification reactions:

NCA - Add **10 µl** of **TE-buffer** to the tube labeled NCA (Negative Control of Amplification)

C+ - Add **10 µl** of **Positive Control DNA MTC-diff / STI (C+_{MTC-diff / STI})** to the tube labeled C+



It is recommended to sediment drops from walls of tubes by short vortexing (1–3 s) before placing them in the thermocycler.



For carrying out decontamination of reaction mix incubate prepared tubes at room temperature for 10–30 min.

8.2.2. Amplification

1. Create a temperature profile on your instrument as follows:

Table 1

“95-65-72 MTC” amplification program for Rotor-Gene 3000/6000 (Corbett Research, Australia); Rotor-Gene Q (QIAGEN, Germany), iCycler iQ5 (Bio-Rad, USA)

Cycle	Temperature, °C	Time	Fluorescence detection	Cycles
Hold	95	15 min	–	1
Cycling	95	15 s	–	5
	65	30 s	–	
	72	15 s	–	
Cycling 2	95	15 s	–	40
	65	30 s	FAM, JOE, ROX, Cy5	

	72	15 s	–	
--	----	------	---	--



If Rotor-Gene 3000/6000 (Corbett Research, Australia); Rotor-Gene Q (QIAGEN, Germany) instruments are being used, then rotor's **well №1** must be filled with any sample tube from this experiment, except for an empty one. If one rotor is loaded with the sample tubes that are being analyzed by different reagents kits, then the loading order of the sample tubes will be the following: first load the tubes with reagents for differentiation, then load the tubes for quantitative detection, lastly load tubes for detection of *Mycobacterium tuberculosis complex*.

Table 2

“95-65-72 MTC” amplification program for SmartCycler II (Cepheid, USA)

<i>Temperature, °C</i>	<i>Time</i>	<i>Cycles</i>
95	900 s	1
95	20 s	45
65	50 s	
72	20 s	

Amplification program for some other models of instruments is specified in Guidelines [2].

2. Adjust the fluorescence channel sensitivity according to the *Important Product Information Bulletin* and Guidelines [2].
3. Insert tubes into the reaction module of the device.
4. Run the amplification program with fluorescence detection.
5. Analyze results after the amplification program is completed.

9. DATA ANALYSIS

Analysis of results is performed by the software of the real-time PCR instrument used by measuring fluorescence signal accumulation in four channels:

- The signal of the Internal Control DNA amplification product is detected in the channel for the **Cy5** fluorophore.
- The signal of human mycobacteria DNA (*M.tuberculosis*) is detected in the channel for the **FAM** fluorophore.
- The signal of bovine mycobacteria DNA (*M.bovis* or *M.bovis* BCG) is detected in the channel for the **JOE** fluorophore.
- The signal of only the vaccine strain (*M.bovis* BCG) is detected in the channel for the **ROX** fluorophore.

Results are interpreted by the interception (or absence of interception) of the fluorescence curve with the threshold line set at the specific level that corresponds to the presence (or

absence) of a *Ct* (*Cp*) value of the DNA sample in the corresponding column of the results grid.

Principle of interpretation is as follows:

- The result is considered to be **positive (+)** if the fluorescence curve has a typical sigmoid form and intercepts the threshold line in the area of exponential fluorescence growth, and if *Ct* and *Cp* values are less than or equal to the boundary values.
- The result is considered to be **negative (–)** if the fluorescence curve does not have a typical sigmoid form and it does not intercept the threshold line, therefore *Ct* (*Cp*) value is absent.
- The result is considered to be **equivocal (>*Ct*)** if the value of the threshold is higher than presented.
- The **invalid** result in a channel is formed of the plurality of the negative values of that channel and negative or equivocal result in **Cy5** channel, which was reproduced after secondary sample analysis.



The threshold values of *Ct* are found in the *Important Product Information Bulletin*, included in the reagents kit.

Positive result in the **FAM** channel implies that human strain (*M.tuberculosis*) is detected.

Positive result in the **JOE** channel implies that bovine strains (*M.bovis* and *M.bovis* BCG) are detected.

Positive result in the **ROX** channel implies that bovine vaccine strain (*M.bovis* BCG) is detected.

Positive result in **Cy5** channel confirms adequate procession of extraction and amplification steps.



Results interpretation from *Mycobacterium tuberculosis complex* (*MTC*) strain differentiation is conducted independently for each channel.



The reagents kit allows detection of specified strains from *M.tuberculosis complex* in mixes (for example, *M.tuberculosis* and *M.bovis* mix or *M.tuberculosis* and *M.bovis* BCG mix). An exception to that is *M.bovis* and *M.bovis* BCG mix, due to the fact that *M.bovis* BCG belongs to the bovine *MTC* strain (*M.bovis*).

The result of the analysis is considered reliable only if the results obtained for Positive and Negative Controls of amplification are correct (see Table 3).

Table 3

Results for controls

Control	Stage for control	Ct value in the channel for fluorophore			
		FAM	JOE	ROX	Cy5
NCA	PCR	-	-	-	-
C+	PCR	+	+	+	+

Table 4

Results interpretation for analyzed clinical samples or microorganism cultures

ДНК	FAM	JOE	ROX	Cy5	Result	Result interpretation
<i>M.tuberculosis</i>	+	Any result possible ¹	Any result possible	+/-	Detected	<i>M.tuberculosis</i> DNA (human species) is detected
	-	Any result possible	Any result possible	+	Not detected	<i>M.tuberculosis</i> DNA (human species) is not detected
	>Ct	Any result possible	Any result possible	+	Equivocal	<i>M.tuberculosis</i> DNA (human species) detection is equivocal. It is recommended to repeat sampling and analysis of material
	->Ct	Any result possible	Any result possible	->Ct	Invalid	<i>M.tuberculosis</i> DNA (human species) – invalid result. It is recommended to repeat sampling and analysis of material
<i>M.bovis</i>	Any result possible	+	-	+/-	Detected	<i>M.bovis</i> DNA (bovine species) is detected
	Any result possible	-	Any result possible	+	Not detected	<i>M.bovis</i> DNA (bovine species) is not detected
	Any result possible	>Ct	-	+	Equivocal	<i>M.bovis</i> DNA (bovine species) detection is equivocal. It is recommended to repeat sampling and analysis of material
	Any result possible	->Ct	Any result possible	->Ct	Invalid	<i>M.bovis</i> DNA (bovine species) – invalid result. It is recommended to repeat sampling and analysis of material
<i>M.bovis</i> is BCG	Any result possible	Any result possible	+	+/-	Detected	<i>M.bovis</i> BCG DNA (vaccine strain) is detected

¹ Any result possible– the analysis result can be either: positive (+), negative (-) or equivocal (>Ct).

	Any result possible	+/-	-	+	Not detected	<i>M.bovis</i> BCG DNA (vaccine strain) is not detected
	Any result possible	Any result possible	>Ct	+	Equivocal	<i>M.bovis</i> BCG DNA (vaccine strain) – detection is equivocal. It is recommended to repeat sampling and analysis of material
	Any result possible	Any result possible	-/>Ct	-/>Ct	Invalid	<i>M.bovis</i> BCG DNA (vaccine strain) – invalid result. It is recommended to repeat sampling and analysis of material

9.1. Results interpretation principle:

- If a positive result (+) is obtained in one of the channels **FAM**, **JOE** or **ROX**, along with a positive or negative result in channel **Cy5**, then either *M.tuberculosis*, *M.bovis* or *M.bovis* BCG is **detected** in the tested sample, respectively. In case of *M.bovis* BCG detection, a positive signal may also be registered in the **JOE** channel.
- If a negative result (–) is obtained in one of the channels **FAM**, **JOE** or **ROX**, along with a positive result in channel **Cy5**, then either *M.tuberculosis*, *M.bovis* or *M.bovis* BCG is **not detected** in the tested sample, respectively.
- If a positive result (+) is obtained in several of the channels **FAM**, **JOE** or **ROX**, then a mix of different strains from *M.tuberculosis* complex is **detected**.



An exception to this is a combination of positive signals in **JOE** and **ROX** channels, indicating the detection of *M.bovis* BCG in the tested sample. Therefore, if the tested sample contains a mix of *M.bovis* BCG and *M.bovis*, then the sample is identified as *M.bovis* BCG.

- If an equivocal result (>Ct) is obtained in one of the channels **FAM**, **JOE** or **ROX**, along with a positive result in channel **Cy5**, then the DNA sample amplification needs to be repeated. If a significant result is not obtained, repeat extraction and DNA amplification steps using the original sample. Obtaining an analogous result (>Ct) is interpreted as an equivocal result.
- If a negative or equivocal result is obtained in channels **FAM**, **JOE** or **ROX**, along with a negative or equivocal result in channel **Cy5**, the result is suggested to be invalid. In this case, repeat the amplification of the sample. If a valid result is not obtained, repeat **extraction and DNA amplification steps using the original sample. Obtaining an analogous result (-/>Ct) is interpreted as invalid.**



The validity of results is assessed independently for each channel.

10. TROUBLESHOOTING

Results of analysis are not taken into account in the following cases:

- If the positive signal is not detected in one or more detection channels for positive control of PCR (C+). In this case, repeat the C+ amplification. If the repeated procedure gives no positive signal, then the reagents kit is not suitable for further use.
- If the positive signal is detected in one or more detection channels for negative control of PCR (NCA). In this case, repeat the amplification no less than for 5 samples of negative control of PCR (NCA). If the repeated procedure still gives a positive signal in at least one sample, the reagents kit is not suitable for further use.

If you have any further questions or if you encounter problems, please contact our Authorized representative in the European Community.

11. TRANSPORTATION

AmpliSens[®] MTC-diff-FRT PCR kit should be transported at 2–8 °C for no longer than 5 days.

12. STABILITY AND STORAGE

All components of the **AmpliSens[®] MTC-diff-FRT** PCR kit are to be stored at 2–8 °C when not in use. All components of the **AmpliSens[®] MTC-diff-FRT** PCR kit are stable until the expiry date stated on the label. The shelf life of reagents before and after the first use is the same, unless otherwise stated.



PCR-mix-1-FL *MTC-diff*, PCR-mix-2-FRT, polymerase (TaqF) and Enzyme UDG are to be stored at the temperature from minus 24 to minus 16 °C



PCR-mix-1-FL *MTC-diff* is to be kept away from light

13. SPECIFICATIONS

13.1. Sensitivity

Table 5

Clinical material	DNA extraction kit	Sensitivity, mb/ml			
		AmpliSens [®] MTC-FRT	AmpliSens [®] MTC-diff-FRT	AmpliSens [®] MTC-FRT	AmpliSens [®] MTC-diff-FRT
		<i>M.tuberculosis</i> (H37 Ra strain)		<i>M.bovis</i> BCG (<i>M.bovis</i> BCG strain)	
PBS-buffer	RIBO-prep	5x10 ²	1x10 ³	1x10 ³	1x10 ³
Urine		1x10 ³	5x10 ³	1x10 ³	1x10 ³
Sputum ² , BAL/BWF		5x10 ²	1x10 ³	1x10 ³	1x10 ³
PBS-buffer	DNA-sorb-B	5x10 ²	1x10 ³	1x10 ³	1x10 ³
Sputum ² , BAL/BWF		5x10 ²	5x10 ³	1x10 ³	5x10 ³
Urine		1x10 ³	5x10 ³	1x10 ³	5x10 ³
10 % homogenate of different tissues	DNA-sorb-C	1x10 ²	1x10 ³	5x10 ²	1x10 ³

13.2. Specificity

The analytical specificity of **AmpliSens[®] MTC-diff-FRT** PCR kit is ensured by the selection of specific primers and probes as well as stringent reaction conditions. The primers and probes have been checked for possible homologies to all sequences published in gene banks by sequence comparison analysis.

The analytical specificity of **AmpliSens[®] MTC-diff-FRT** PCR kit was assessed during strain analysis of mycobacteria from *M.tuberculosis complex*, nontuberculous mycobacteria, and also other microorganism strains that induce illnesses in similar locations.

In order to define the analytical specificity on different microorganism strains (with concentration no less than 5x10⁸ mb/ml), 116 control strains or clinical isolators were tested. Five of them were included into *M.tuberculosis complex*, 31 strains were nontuberculous mycobacteria (NTM), and the remaining 80 strains belong to other genii and families. The analytical specificity was assessed based on the absence of the positive DNA amplification result for samples not included in *M.tuberculosis complex*, and also based on the presence of the positive DNA amplification result in complementary detection channel for differentiation of mycobacterial strains of the *M.tuberculosis complex*.

² Concentration in 1 ml of sputum, treated with reagent for pre-treatment of mucous material "Mucolysin".

List of reference strains:

- Mycobacteria, that are included in *Mycobacterium tuberculosis* complex: *M.tuberculosis*, *M.bovis*, *M.bovis* BCG-1, etc.
- Nontuberculous mycobacteria: *M.avium*, *M.paratuberculosis*, *M.xenopi*, *M.gordonae*, *M.ulcerans*, *M.phlei*, *M.intracellulare*, *M.kansasii*, *M.fortuitum*.
- Bacteria belonging to other genii and families: *Brucella*, *Campylobacter*, *Chlamyphila*, *Cryptococuss*, *Enterobacter*, *Enterococcus*, *E.coli*, *Klebsiella*, *Listeria*, *Moraxella*, *Neisseria*, *Pantoea*, *Pasteurella*, *Proteus*, *Pseudomonas*, *Salmonella*, *Shigella*, *Staphylococcus*, *Streptococcus*.

The 100% clinical specificity of **AmpliSens[®] MTC-diff-FRT** PCR kit was confirmed in laboratory clinical trials.














14. REFERENCES

1. Handbook “Sampling, Transportation, and Storage of Clinical Material for PCR diagnostics”, developed by Federal Budget Institute of Science “Central Research Institute for Epidemiology” of Federal Service for Surveillance on Consumers’ Rights Protection and Human Well-Being, Moscow, 2010.
2. Guidelines to the **AmpliSens[®] MTC-diff-FRT** PCR kit test for differentiation of the DNA of *Mycobacterium tuberculosis* complex (MTC) including the human (*M.tuberculosis*), the bovine (*M.bovis*) and also the vaccine strain (*M.bovis* BCG) in the clinical material and microorganism cultures by the polymerase chain reaction (PCR) with real-time fluorescence hybridization detection developed by Federal Budget Institute of Science “Central Research Institute for Epidemiology”.

15. QUALITY CONTROL

In compliance with Federal Budget Institute of Science “Central Research Institute for Epidemiology” ISO 13485-Certified Quality Management System, each lot of the **AmpliSens® MTC-diff-FRT** PCR kit has been tested against predetermined specifications to ensure consistent product quality.

16. KEY TO SYMBOLS USED

	Catalogue number		Caution
	Batch code		Sufficient for
	Version		Expiration Date
	<i>In vitro</i> diagnostic medical device		Consult instructions for use
	Temperature limitation		Keep away from sunlight
	Manufacturer	NCA	Negative control of amplification
	Date of manufacture	C+	Positive control of amplification
	Authorised representative in the European Community	C-	Negative control of extraction
		IC	Internal control